Review our commercial product billing guide

Dec. 2023Important Notices
Pennsylvania Act 1 of 2023, signed into law this May, requires insurance policies to cover all costs associated with one supplemental breast screening every year for women with increased risk of breast cancer via MRI or ultrasound.

To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.

We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.

If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.

Recent Announcements

Voluntary nationwide recall: Atorvastatin (Alkem – October)

Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.
Nov. 2025Pharmacy Updates

October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.
Oct. 2025Pharmacy Updates

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates